InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China
Germany-based biopharma InflaRx N.V. (Nasdaq: IFRX) has revealed an amendment to its underlying deal with...
Elpiscience Receives IND Approval for ES014 in China
Shanghai-based Elpiscience Biopharmaceuticals Inc. has announced receiving Investigational New Drug (IND) approval in China to...
Ablaze Pharma and Yonghe Partner for Targeted Radiotherapy Development
China-based Ablaze Pharma and Yonghe Pharmaceutical have struck a partnership agreement for the research and...
InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...
Hainan Poly Pharm Receives FDA Approval for Generic Lincomycin
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...
Innovent Biologics’ GFH925 Receives Breakthrough Therapy Designation
China’s Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics (HKG: 1801) has...
Sichuan Healthcare Security Administration Announces VBP for Oral Implant Systems
The Sichuan Provincial Healthcare Security Administration has released a notification regarding the inter-provincial alliance volume-based...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...
Huadong Medicine’s Lanluma V and X Approved for Use in Hainan
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval from the Hainan Medical...
Antengene and MSD Collaborate on Global Clinical Study for ATG-037
China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp...
IASO Biotherapeutics Receives FDA Approval for CT103A IND Application
China-based IASO Biotherapeutics has announced approval from the US FDA for an Investigational New Drug...
Shenzhen Würzburg Dynamics Raises RMB 100 Million in Series A Financing Round
China-based Shenzhen Würzburg Dynamics has reportedly raised RMB 100 million (USD 14.36 million) in a...
AcornMed Raises RMB 200 Million in Series B Financing Led by Yikai Venture Capital
AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million...
CSPC’s NBL-020 Receives FDA IND Approval for Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving Investigational New Drug (IND) approval...
Jiangsu Chia Tai Tianqing’s TQB2102m Gains NMPA Clinical Approval
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd’s (CTTQ) Category 1 biologic product TQB2102m, an HER2...
WuXi XDC Partners with GeneQuantum for ADC Development
China-based WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a...
Hengrui Pharmaceuticals Receives New Approval for Remimazolam Tosylate
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced one new supplementary approval for its gamma-aminobutyric...
Neurophth Partners with Apellis for Gene Therapy Development in AMD
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with US firm...
Jing Medicine’s HJM-353 Gains Clinical Trial Approvals in US and China
China-based Jing Medicine Technology (Shanghai) Co., Ltd’s HJM-353 has obtained clinical trial approvals in the...
Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round
China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67...